Table 3.

BzATP pharmacology of alanine-substituted mutants

	n	EC50 (μm)	pEC50	ϵ′
WT	6	17.38	4.76 ± 0.13	0.69 ± 0.03
H33A	13	7.94	5.10 ± 0.08	0.66 ± 0.09
Q37A	6	72.44	4.14 ± 0.05	0.26 ± 0.02**
I40A	5	1.51	5.82 ± 0.03	0.86 ± 0.03
L41A	6	33.11	4.48 ± 0.02	0.32 ± 0.02**
Y43A	7	1.26	5.90 ± 0.13	0.90 ± 0.04*
F44A	11	1.00	5.99 ± 0.06	0.80 ± 0.03
I50A	7	37.15	4.43 ± 0.09	0.33 ± 0.05**
I328A	5	1.38	5.86 ± 0.04	0.89 ± 0.01**
P329A	5	3.47	5.46 ± 0.11	0.66 ± 0.01
N333A	7	4.07	5.39 ± 0.06	0.94 ± 0.02**
L338A	10	74.13	4.13 ± 0.11	0.28 ± 0.05**
T339A	6	8.51	5.07 ± 0.09	0.96 ± 0.03**
S340A	7	75.86	4.12 ± 0.07	0.31 ± 0.04**
G342A	5	63.10	4.20 ± 0.04	0.36 ± 0.01**
V343A	4	1.91	5.72 ± 0.13	1.01 ± 0.15**
G344A	8	91.20	4.04 ± 0.05	0.11 ± 0.02**
S345A	5	21.38	4.67 ± 0.13	0.42 ± 0.03*

Data from experiments like those pictured in Figure 3.

^* and ^** denote differences in ϵ′ (equal to Y_max,BzATP/Y_max,ATP) between WT and mutant receptors at p<0.05 and p<0.01, respectively.